|Bid||144.42 x 100|
|Ask||144.50 x 200|
|Day's Range||143.83 - 144.81|
|52 Week Range||106.48 - 148.84|
|PE Ratio (TTM)||32.49|
|Dividend & Yield||1.70 (1.18%)|
|1y Target Est||N/A|
Stryker's (SYK) diverse product portfolio alongside acquisition-driven strategy would continue to boost growth prospects. However, competition in the Chinese market raise concern.
Accuray's (ARAY) Radixact system leverages on its flagship TomoTherapy platform. The company's top-line growth is dependent on TomoTherapy system sales.
Positive tidings on the regulatory front have favored Globus Medical (GMED) of late. The company's latest regulatory progress would lend it a competitive edge in the global niche space.